MicroRNA-340 inhibits prostate cancer cell proliferation and metastasis by targeting the MDM2-p53 pathway.

An increasing number of studies have demonstrated the important role of microRNAs (miRNAs) in modulating cancer progression and metastasis, but the mechanisms by which miRNAs regulate prostate cancer (PCa) tumorigenesis remain poorly understood. In the present study, we found that miR-340 may act as a tumor suppressor based on our finding that it was significantly downregulated in PCa tumor tissues and cell lines. Moreover, the expression of miR-340 was found to be correlated with the inhibition of cell proliferation, migration and invasion in vitro, and had a suppressive effect on tumor growth in a xenograft mouse model as well. The suppressive effect of miR-340 overexpression was observed in cell lines DU145 and BPH-1 which express wild-type (WT) p53. However, in the p53-null PC-3 cell line, the suppressive effect was not found, indicating that miR-340 may play a critical role in the p53 pathway. Further investigation revealed that mouse double minute 2 (MDM2), an important regulator of p53, was targeted by miR-340 through the direct binding to the 3'UTR of MDM2, which inhibited MDM2 translation. In addition, miR-340 expression stabilized p53 protein levels which caused an increase in p21 expression but a decrease in the anti‑apoptotic protein, BCL-2, in the p53 WT cell lines. Moreover, the miR-340-mediated inhibition of cell progression was mitigated by re-expressing MDM2 in the stable miR‑340-overexpressing PCa cell line, which harbors WT p53. Our findings suggest that miR-340 may function as a novel tumor suppressor in PCa through the MDM2-p53 pathway by directly targeting MDM2, which may be a promising miRNA-targeted therapy for PCa.

[1]  A. Levine,et al.  mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein , 1996, Molecular and cellular biology.

[2]  Mauro Biffoni,et al.  The miR-15a–miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities , 2008, Nature Medicine.

[3]  T. Nikolskaya,et al.  Reconstitution of the ERG Gene Expression Network Reveals New Biomarkers and Therapeutic Targets in ERG Positive Prostate Tumors , 2015, Journal of Cancer.

[4]  X. Mao,et al.  Upregulation of miR‐153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer , 2013, The Prostate.

[5]  Wei Wang,et al.  MicroRNA-340 suppresses osteosarcoma tumor growth and metastasis by directly targeting ROCK1. , 2013, Biochemical and biophysical research communications.

[6]  Hui Wang,et al.  MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. , 2005, Current cancer drug targets.

[7]  V. Spiegelman,et al.  MicroRNA-340 as a modulator of RAS-RAF-MAPK signaling in melanoma. , 2014, Archives of biochemistry and biophysics.

[8]  Robert A. Weinberg,et al.  Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model , 2010, Nature Biotechnology.

[9]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[10]  Bo Jiang,et al.  Role of MicroRNAs in Prostate Cancer Pathogenesis. , 2015, Clinical genitourinary cancer.

[11]  Miguel Srougi,et al.  Abnormal Expression of MDM2 in Prostate Carcinoma , 2001, Modern Pathology.

[12]  Chang-jin Shi,et al.  A novel organoselenium compound induces cell cycle arrest and apoptosis in prostate cancer cell lines. , 2003, Biochemical and biophysical research communications.

[13]  Z. Hall Cancer , 1906, The Hospital.

[14]  Zhu Wang,et al.  Screening and identification of significant genes related to tumor metastasis and PSMA in prostate cancer using microarray analysis. , 2013, Oncology reports.

[15]  Libing Song,et al.  Double-negative feedback loop between ZEB2 and miR-145 regulates epithelial-mesenchymal transition and stem cell properties in prostate cancer cells , 2014, Cell and Tissue Research.

[16]  Markus Vogt,et al.  MicroRNA-205, a novel regulator of the anti-apoptotic protein Bcl2, is downregulated in prostate cancer. , 2013, International journal of oncology.

[17]  U. Pastorino,et al.  Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction , 2014, Cell Death and Disease.

[18]  Hirofumi Tanaka,et al.  Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 , 1997, FEBS letters.

[19]  Y. Wang,et al.  Low miR-34a and miR-192 are associated with unfavorable prognosis in patients suffering from osteosarcoma. , 2015, American journal of translational research.

[20]  Xin Huang,et al.  Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction. , 2009, Journal of medicinal chemistry.

[21]  Jingqiang Wang,et al.  Identification of miR-133b and RB1CC1 as Independent Predictors for Biochemical Recurrence and Potential Therapeutic Targets for Prostate Cancer , 2014, Clinical Cancer Research.

[22]  Guillermina Lozano,et al.  Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 , 1995, Nature.

[23]  S. Majid,et al.  The Role of miR-18b in MDM2-p53 Pathway Signaling and Melanoma Progression , 2013, Journal of the National Cancer Institute.

[24]  D. Bartel,et al.  The impact of microRNAs on protein output , 2008, Nature.

[25]  L. Chung,et al.  Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis , 2014, Oncogene.

[26]  Robert A. Weinberg,et al.  Tumor Metastasis: Molecular Insights and Evolving Paradigms , 2011, Cell.

[27]  H. Shima,et al.  Growth of human prostate cancer cells is significantly suppressed in vitro with sodium butyrate through apoptosis. , 2011, Oncology reports.

[28]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[29]  O. Myklebost,et al.  Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Qin Chen,et al.  miR‐146a functions as a tumor suppressor in prostate cancer by targeting Rac1 , 2014, The Prostate.

[31]  A. Seth,et al.  MicroRNAs in prostate cancer: from biomarkers to molecularly-based therapeutics , 2012, Prostate Cancer and Prostatic Diseases.

[32]  P. Verde,et al.  miR-340 inhibits tumor cell proliferation and induces apoptosis by targeting multiple negative regulators of p27 in non-small cell lung cancer , 2014, Oncogene.

[33]  M. Guo,et al.  miR-340 inhibits glioblastoma cell proliferation by suppressing CDK6, cyclin-D1 and cyclin-D2. , 2015, Biochemical and biophysical research communications.

[34]  Xiao-nan Wang,et al.  miR‐340 inhibition of breast cancer cell migration and invasion through targeting of oncoprotein c‐Met , 2011, Cancer.

[35]  Junming Guo,et al.  Gastric juice miR-129 as a potential biomarker for screening gastric cancer , 2013, Medical Oncology.

[36]  Sudhir Agrawal,et al.  Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[37]  R. Roby,et al.  MicroRNA-940 suppresses prostate cancer migration and invasion by regulating MIEN1 , 2014, Molecular Cancer.

[38]  Qunshu Zhang,et al.  Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells , 2010, Cell Death and Disease.

[39]  A. Esquela-Kerscher,et al.  miR-888 is an expressed prostatic secretions-derived microRNA that promotes prostate cell growth and migration , 2014, Cell cycle.